Ovarian cancer in Asia: incidence, mortality in 2022, and future projections to 2050.
4 affiliations
- 1Department of Obstetrics and Gynecology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, P. R. China.
- 2Department of Obstetrics and Gynecology, Punan Branch of Renji Hospital, Shanghai Jiao Tong University School of Medicine (Punan Hospital in Pudong, New district, Shanghai), Shanghai, China.
- 3Galactophore Department, Galactophore Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China. [email protected].
- 4Department of Obstetrics and Gynecology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, P. R. China. [email protected].
Abstract
Ovarian cancer continues to carry a poor prognosis, particularly in resource-limited settings. Using estimates from the International Agency for Research on Cancer, we conducted a secondary analysis of ovarian cancer burden across 47 Asian countries in 2022 and projected the burden through 2050. Age-standardized incidence and mortality rates (ASIR, ASMR) were obtained from GLOBOCAN 2022, using the Segi-Doll standard population. Associations with the Human Development Index (HDI) were assessed using Spearman's correlation. Age-period-cohort (APC) modeling was applied to explore generational risk patterns based on mortality data from 1993 to 2022. In 2022, Asia accounted for 178.2 thousand new cases and 109.5 thousand deaths. ASIR and ASMR were 6.2 and 3.7 per 100,000, respectively. Brunei Darussalam exhibited the highest incidence (13.2 per 100,000), and the Philippines had the highest mortality (7.5 per 100,000). APC analysis revealed higher cohort-specific risks among women born in more recent birth cohorts relative to those born in 1949-1957 (reference cohort). ASIR (r = 0.425, P < 0.05) and ASMR (r = 0.309, P < 0.05) were positively correlated with HDI among women aged ≥ 50 years. High body-mass index emerged as the leading modifiable risk factor contributing to mortality, with the highest contributions in Kuwait (22.3%), Qatar (21.3%) and Jordan (20.2%). Under constant rates, ovarian cancer cases and deaths in Asia are projected to rise to 265.9 thousand and 183.6 thousand by 2050, with the fastest increases in low-HDI countries (124% cases; 137% deaths). These findings highlight substantial heterogeneity across countries, generations, and development levels, underscoring the need for age-targeted, development-sensitive prevention and health-system strategies in Asia.
Related
- The Changing Global Epidemiology of Early-Onset Colorectal Cancer: Incidence Trends, Modifiable Risk Factors, and Future Burden Projections
- Racial disparities in ovarian cancer incidence and mortality in Brazil: a population based analysis
- Incidence, prevalence, mortality and survival trends in women with endometrial-, ovarian- and cervical cancer in the Nordic countries (1980–2023) with focus on younger women (0–49 years old)
- Age, period, and cohort effects in the population-level incidence and mortality of cancer types associated with early onset increases in Australia
- Global, Regional, and National Burden of Ovarian Cancer Among Women of Reproductive Age, 1990–2021, with Projections to 2040: A Global Burden of Disease Study 2021 Analysis
BibTeX
@article{fu2026ovarian,
title = {{Ovarian cancer in Asia: incidence, mortality in 2022, and future projections to 2050.}},
author = {Yu Fu and Yangyang Xu and Baohua Zhang and Mengxia Fu and Huizhen Sun},
journal = {BMC public health},
year = {2026},
month = jul,
doi = {10.1186/s12889-026-28608-2},
url = {https://europepmc.org/article/MED/42894150},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Ovarian cancer in Asia: incidence, mortality in 2022, and future projections to 2050.
AU - Yu Fu
AU - Yangyang Xu
AU - Baohua Zhang
AU - Mengxia Fu
AU - Huizhen Sun
PY - 2026
DA - 2026/07/01
JO - BMC public health
DO - 10.1186/s12889-026-28608-2
UR - https://europepmc.org/article/MED/42894150
AB - Ovarian cancer continues to carry a poor prognosis, particularly in resource-limited settings. Using estimates from the International Agency for Research on Cancer, we conducted a secondary analysis of ovarian cancer burden across 47 Asian countries in 2022 and projected the burden through 2050. Age-standardized incidence and mortality rates (ASIR, ASMR) were obtained from GLOBOCAN 2022, using the Segi-Doll standard population. Associations with the Human Development Index (HDI) were assessed using Spearman's correlation. Age-period-cohort (APC) modeling was applied to explore generational risk patterns based on mortality data from 1993 to 2022. In 2022, Asia accounted for 178.2 thousand new cases and 109.5 thousand deaths. ASIR and ASMR were 6.2 and 3.7 per 100,000, respectively. Brunei Darussalam exhibited the highest incidence (13.2 per 100,000), and the Philippines had the highest mortality (7.5 per 100,000). APC analysis revealed higher cohort-specific risks among women born in more recent birth cohorts relative to those born in 1949-1957 (reference cohort). ASIR (r = 0.425, P < 0.05) and ASMR (r = 0.309, P < 0.05) were positively correlated with HDI among women aged ≥ 50 years. High body-mass index emerged as the leading modifiable risk factor contributing to mortality, with the highest contributions in Kuwait (22.3%), Qatar (21.3%) and Jordan (20.2%). Under constant rates, ovarian cancer cases and deaths in Asia are projected to rise to 265.9 thousand and 183.6 thousand by 2050, with the fastest increases in low-HDI countries (124% cases; 137% deaths). These findings highlight substantial heterogeneity across countries, generations, and development levels, underscoring the need for age-targeted, development-sensitive prevention and health-system strategies in Asia.
SN - 1471-2458
ER -